The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease

Current Opinion in Neurology

Volumn 26, Issue 6, 2013, Pages 646-655

  Vandenberghe, Rik ^a,b,c   Adamczuk, Katarzyna ^a,c   Laere, Koen Van ^c  

^a KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alzheimer's disease; Amyloid PET; Clinical utility

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE; FLUTEMETAMOL F 18; PITTSBURGH COMPOUND B; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); FLUORODEOXYGLUCOSE F 18; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; COMORBIDITY; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; INTERMETHOD COMPARISON; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRIMARY PROGRESSIVE APHASIA; REVIEW; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; BRAIN; CEREBROSPINAL FLUID; DIAGNOSTIC USE; METABOLISM; REPRODUCIBILITY; SCINTISCANNING;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; BRAIN; FLUORODEOXYGLUCOSE F18; HUMANS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS;

EID: 84892369387     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000036     Document Type: Review

References (59)

1. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging- Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8:1-13.
2. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry of Alzheimer's Disease. 2. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41:479-486.
3. Thal DR, Rüb U, Orantes M, Braak H. Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58:1791-1800.
4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991; 82:239-259.
5. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer disease centers, 2005-2010. J Neuropathol Exp Neurol 2012; 71:266-273.
6. Ni R, Gillberg PG, Bergfors A, et al. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain 2013; 136:2217-2227.
7. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 2010; 68:319-329.
8. Wolk DA, Zhang Z, Boudhar S, et al. Amyloid imaging in Alzheimer's disease: Comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 2012; 83:923-926.
9. Landau SM, Lu M, Joshi AD, et al. Comparing PET imaging and CSF measurements of Ab. Ann Neurol 2013. [Epub ahead of print]
10. Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11C-PIB and 18F-florbetaben for Ab imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012; 39:983-989.
11. Rowe CC, Pejoska S, Mulligan RS, et al. Head-to-head comparison of 11C-PIB and 18F-AZD4694 (NAV4694) for b-amyloid imaging in aging and dementia. J Nucl Med 2013; 54:880-886.
12. Landau SM, Breault C, Joshi AD, et al. Amyloid-b imaging with Pittsburgh compound B and florbetapir: Comparing radiotracers and quantification methods. J Nucl Med 2013; 54:70-77.
13. Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012; 53:378-384.
14. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011; 52:1210-1217.
15. Cselé nyi Z, Jönhagen ME, Forsberg A, et al. Clinical validation of 18F-AZD4694, an amyloid-b-specific PET radioligand. J Nucl Med 2012; 53:415-424.
16. Rinne JO, Wong DF, Wolk DA, et al. [18F]flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid b detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol 2012; 124:833-845.
17. Ng S, Villemagne VL, Berlangieri S, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007; 48:547-552.
18. Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-b assessed by florbetapir 18F-PET and 18-month cognitive decline: A multicenter study. Neurology 2012; 79:1636-1644.
19. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol 2012; 10:424-435.
20. Tiepolt S, Barthel H, Butzke D, et al. Influence of scan duration on the accuracy of b-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers. Eur J Nucl Med Mol Imaging 2013; 40:238-244.
21. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013; 9:e1-16.
22. Vandenberghe R, Nelissen N, Salmon E, et al. Binary classification of 18F-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI. Neuroimage 2012; 64C:517-525.
23. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-b laques: A prospective cohort study. Lancet Neurol 2012; 11:669- 678.
24. Kantarci K, Yang C, Schneider JA, et al. Antemortem amyloid imaging and bamyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2012; 33:878-885.
25. Driscoll I, Troncoso JC, Rudow G, et al. Correspondence between in vivo 11C-PIB PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 2012; 124:823-831.
26. Ikonomovic MD, Abrahamson EE, Price JC, et al. Early AD pathology in a11C-PIB-negative case: A PIB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol 2012; 123:433-447.
27. Schöll M, Wall A, Thordardottir S, et al. Low PIB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79:229-236.
28. Thurfjell L, Lötjönen J, Koikkalainen R, et al. Combination of biomarkers: PET 18F-flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegenerative Dis 2012; 10:246-249.
29. Duara R, Loewenstein DA, Shen Q, et al. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimers Dement 2013; 9:295-301.
30. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's association criteria for preclinical Alzheimer disease. Ann Neurol 2012; 71:765-775.
31. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on b-amyloid in normal elderly. Ann Neurol 2013; 73:472-480.
32. Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010; 23:185-198.
33. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77:2034-2042.
34. Furst AJ, Rabinovici GD, Rostomian AH, et al. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging 2012; 33:215-225.
35. Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013; 136:844-858.
36. Gefen T, Gasho K, Rademaker A, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain 2012; 135:1554-1565.
37. Mesulam MM. Behavioral neuroanatomy: large-scale networks, association cortex, frontal syndromes, the limbic system and hemispheric specializations (p. 1-120). Aging Alzheimer's disease and dementia-Clinical and neurobiological perspectives (p. 439-522). In: Mesulam MM, editor. Principles of behavioral and cognitive neurology. New York, NY: Oxford University Press; 2000.
38. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009; 1:371-380.
39. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013; 40:104-114.
40. Ossenkoppele R, Prins ND, Pijnenburg YAL, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013; 9:414-421.
41. Grundman M, Pontecorvo MJ, Salloway SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients ith progressive cognitive decline. Alzheimer Dis Assoc Disord 2013; 27:4-15.
42. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72:578-586.
43. Schipke CG, Peters O, Heuser I, et al. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33:416-422.
44. Mathis CA, Kuller LH, Klunk WE, et al. In vivo assessment of amyloid-b deposition in nondemented very elderly subjects. Ann Neurol 2013; 73:751-761.
45. Hornberger M, Wong S, Tan R, et al. In vivo and postmortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease. Brain 2012; 135:3015-3025.
46. Snitz BE, Weissfeld LA, Lopez OL, et al. Cognitive trajectories associated with b-amyloid deposition in the oldest-old without dementia. Neurology 2013; 80:1378-1384.
47. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130:2636-2645.
48. Leyton CE, Villemagne VL, Savage S. Subtypes of progressive aphasia: Application of the international consensus criteria and validation using b-amyloid imaging. Brain 2011; 134:3030-3043.
49. Mesulam MM, Wieneke C, Thompson C. Quantitative classification of primary progressive aphasia at early and mild impairment stages. Brain 2012; 135:1537-1553.
50. Lee JH, Kim SH, Kim GH, et al. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology 2011; 77:18-25.
51. Gurol ME, Viswanathan A, Gidicsin C, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: A positron emission tomography/magnetic resonance imaging study. Ann Neurol 2013; 73:529-536.
52. Dhollander I, Nelissen N, Van Laere K, et al. In vivo amyloid imaging in cortical superficial siderosis. J Neurol Neurosurg Psychiatry 2011; 82:469-471.
53. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79:1331- 1338.
54. Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-b deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional study. Lancet Neurol 2012; 11:1057-1065.
55. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795-804.
56. Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain b-amyloid load approaches a plateau. Neurology 2013; 80:890-896.
57. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12:207-216.
58. Chételat G, La Joie R, Villain N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage Clinical 2013; 2:356-365.
59. Vandenberghe R, Adamczuk K, Dupont P, et al. Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. NeuroImage Clinical 2013; 2:497-511.